STOCK TITAN
  1. Home
  2. News
  3. TPST

Tempest Therapeutics, Inc. - TPST STOCK NEWS

Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.

Tempest Therapeutics, Inc. (TPST) is a biotechnology company focused on the development of small molecule therapeutics that modulate anti-tumor immunity pathways.

Tempest's mission is to pioneer novel treatments for cancer by leveraging a balanced and deep pipeline of small molecule therapeutics. These therapeutics are designed to modulate distinct immune response pathways that are crucial for mounting an effective anti-tumor response. Developed by Inception Sciences, a Versant Ventures-affiliated drug discovery engine, the company’s pipeline includes first-in-class and best-in-class molecules.

The company’s leading product candidates, TPST-1120 and TPST-1495, are in the clinical stage. TPST-1120 aims to inhibit its target to promote anti-tumor immunity, while TPST-1495 is designed to activate tumor-specific immune responses. These candidates are developed to address significant unmet medical needs across a range of cancers.

Tempest Therapeutics has assembled a highly experienced team of drug developers specializing in small molecules and immuno-oncology. This team is dedicated to advancing these programs through clinical trials and eventually to market. The company's robust research and development efforts are backed by a syndicate of leading venture capital firms based in the United States and China, providing strong financial support and strategic guidance.

Recent achievements for Tempest Therapeutics include the initiation and progress of randomized clinical trials, showcasing the company’s commitment to evidence-based development and regulatory approval. With a focus on innovation and patient outcomes, Tempest Therapeutics is well-positioned to make significant contributions to the field of oncology.

For more detailed information on the company’s latest updates, news, and financial performance, you can contact Sylvia Wheeler and Aljanae Reynolds at Wheelhouse Life Science Advisors.

News

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Rhea-AI Summary
Tempest Therapeutics, Inc. announces positive clinical data for TPST-1120, a PPAR⍺ antagonist, showing clinical activity in PD-1 inhibitor refractory and immune compromised cancers. The Company plans to move TPST-1120 into a Phase 3 trial in HCC after successful Phase 1 and Phase 1b/2 trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.2%
Tags
clinical trial
-
News

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Tempest Therapeutics, Inc. (TPST) reported positive randomized first-line HCC data for TPST-1120 combination therapy, new biomarker data, and plans for Phase 3 trials. Financially, Tempest ended 2023 with $39.2 million in cash, showing improved net loss and reduced expenses compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
earnings
-
News

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

Rhea-AI Summary
Tempest Therapeutics, Inc. presents promising preclinical data at SITC 2024 Spring Scientific Meeting for TPST-1120, a selective PPAR⍺ antagonist showing potent anti-tumor activity in various cancer models. Positive Phase 1 and 2 results support late-stage clinical development in liver cancer patients, with plans for pivotal study. Data indicates inhibition of PPAR⍺ as an effective cancer treatment strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Rhea-AI Summary
Tempest Therapeutics (TPST) collaborates with BIDMC to present preclinical data on TPST-1120 for renal cell carcinoma at AACR Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.09%
Tags
conferences clinical trial
-
News

Tempest to Present at the 44th Annual TD Cowen Healthcare Conference

Rhea-AI Summary
Tempest Therapeutics, Inc. (TPST) to present at the 44th Annual TD Cowen Healthcare Conference on March 4, 2024, focusing on cancer therapeutics development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences
-
News

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) has granted two employees nonqualified stock options to purchase 45,500 shares of its common stock under the Company’s 2023 Inducement Plan. The stock options will vest over a four-year period, with 25% of each of the options vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
News

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) announced the grant of a nonqualified stock option to purchase 4,500 shares of its common stock to an employee under the Company’s 2023 Inducement Plan. The option will vest over a four-year period, with 25% vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
none
-
News

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) granted one employee a nonqualified stock option to purchase 7,650 shares of its common stock under the Company’s 2023 Inducement Plan. The stock option will vest over a four-year period, with 25% of the option vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none
-
News

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) to participate in fireside chat at 35th Annual Piper Sandler Healthcare Conference. The company is a clinical-stage oncology company focusing on first-in-class therapeutics combining targeted and immune-mediated mechanisms. Management will be part of the discussion on November 28, 2023, at 3:00 p.m. ET. The live or archived recording can be accessed on the Tempest website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.25%
Tags
conferences
News

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
TPST - Tempest Therapeutics, Inc. reports superior results for TPST-1120 in liver cancer study, strengthening balance sheet. Multiple study endpoints showed promising results, including a 30% confirmed objective response rate and a median progression-free survival of 7 months for TPST-1120 arm. The company also plans to advance TPST-1120 into a registrational study and reported positive financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.31%
Tags
earnings

FAQ

What is the current stock price of Tempest Therapeutics (TPST)?

The current stock price of Tempest Therapeutics (TPST) is $0.7116 as of December 20, 2024.

What is the market cap of Tempest Therapeutics (TPST)?

The market cap of Tempest Therapeutics (TPST) is approximately 31.1M.

What does Tempest Therapeutics, Inc. do?

Tempest Therapeutics is focused on the development of small molecule therapeutics that modulate anti-tumor immunity pathways to treat cancer.

What are Tempest Therapeutics' main product candidates?

The main product candidates are TPST-1120 and TPST-1495, which are designed to inhibit and activate specific targets to promote anti-tumor immunity.

Who developed Tempest Therapeutics' molecules?

The molecules were developed by Inception Sciences, a drug discovery engine affiliated with Versant Ventures.

What makes Tempest Therapeutics' pipeline unique?

Tempest Therapeutics' pipeline is balanced and deep, consisting of first-in-class and best-in-class molecules that modulate distinct immune response pathways.

Who are the key contacts for investor and media inquiries?

Key contacts are Sylvia Wheeler and Aljanae Reynolds at Wheelhouse Life Science Advisors.

What type of cancers does Tempest Therapeutics target?

Tempest Therapeutics targets a range of diverse cancers representing significant unmet medical needs.

What is the core mission of Tempest Therapeutics?

The core mission is to pioneer novel treatments for cancer by leveraging small molecule therapeutics that modulate anti-tumor immunity pathways.

What recent achievements has Tempest Therapeutics made?

Recent achievements include the initiation and progress of randomized clinical trials as part of their clinical development programs.

Who supports Tempest Therapeutics financially?

Tempest is backed by leading venture capital firms based in the United States and China.

How can I get the latest updates on Tempest Therapeutics?

You can get the latest updates by following the news section or contacting Sylvia Wheeler and Aljanae Reynolds at Wheelhouse Life Science Advisors.

Stock TPST logo
Tempest Therapeutics, Inc.

Nasdaq:TPST

TPST Rankings

#5112 Ranked by Market Cap
N/A Ranked by Dividends

TPST Stock Data

31.10M
43.57M
0.24%
23.02%
10.47%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE